Our group have developed aptamer-guided therapies such as aptamer-CD133 and aptamer-EpCAM conjugates for cancer treatments in preclinical studies and demonstrated low cytotoxicity, great binding affinity and penetration ability, and high efficacy for CSC targeting [103–104]. Here, PROM1 is linked to cancer.